RECRUITING

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Conditions

Healthy Subject Hematologic and Lymphocytic Disorder Hematopoietic and Lymphoid Cell Neoplasm Immune System Disorder Malignant Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.

Official Title

Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls

Quick Facts

Study Start:2017-04-12

Study Completion:2026-04-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03207854

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer * Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and/or immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura \[ITP\], etc.) are involved * Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus \[SLE\], rheumatoid arthritis \[RA\], Crohn's disease) and not taking any immunosuppressive medications * Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project	* Unable to give informed consent to specimen collection * Known human immunodeficiency virus (HIV) positive status * Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers * Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)

Inclusion Criteria

Exclusion Criteria

* All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer
* Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and/or immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura \[ITP\], etc.) are involved
* Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus \[SLE\], rheumatoid arthritis \[RA\], Crohn's disease) and not taking any immunosuppressive medications
* Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project

* Unable to give informed consent to specimen collection
* Known human immunodeficiency virus (HIV) positive status
* Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers
* Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)

Contacts and Locations

Study Contact

Arta Zenunovic

CONTACT

323-442 7828

Arta.zenunovic@med.usc.edu

Principal Investigator

Casey O'Connell, MD

PRINCIPAL_INVESTIGATOR

University of Southern California

Study Locations (Sites)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

United States

Collaborators and Investigators

Sponsor: University of Southern California

Casey O'Connell, MD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-04-12

Study Completion Date2026-04-12

Study Record Updates

Study Start Date2017-04-12

Study Completion Date2026-04-12

Terms related to this study

Additional Relevant MeSH Terms

Healthy Subject
Hematologic and Lymphocytic Disorder
Hematopoietic and Lymphoid Cell Neoplasm
Immune System Disorder
Malignant Neoplasm